Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
Background: Neuroendocrine neoplasms are a group of tumors deriving from neural crest. They can be located in every tissue, but most commonly in gastrointestinal tract. Targeted therapy with use of radionuclides is an available and acceptable way of treatment, but its long-term safety is still to be...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/1/185 |
| _version_ | 1797431344468328448 |
|---|---|
| author | Marek Saracyn Adam Daniel Durma Barbara Bober Maciej Kołodziej Arkadiusz Lubas Waldemar Kapusta Stanisław Niemczyk Grzegorz Kamiński |
| author_facet | Marek Saracyn Adam Daniel Durma Barbara Bober Maciej Kołodziej Arkadiusz Lubas Waldemar Kapusta Stanisław Niemczyk Grzegorz Kamiński |
| author_sort | Marek Saracyn |
| collection | DOAJ |
| description | Background: Neuroendocrine neoplasms are a group of tumors deriving from neural crest. They can be located in every tissue, but most commonly in gastrointestinal tract. Targeted therapy with use of radionuclides is an available and acceptable way of treatment, but its long-term safety is still to be determined, especially with sensitive methods. Methods: Study was performed on a group of 42 patients. They underwent full cycle (4 courses; 8–12 weekly intervals) of radioligand therapy with [<sup>177</sup>Lu]Lu-DOTATATE alone or tandem therapy with [<sup>177</sup>Lu]Lu-DOTATATE+[<sup>90</sup>Y]Y-DOTATATE. Late and long-term marrow and renal complications were assessed. Analysis focused on comparing data before first, fourth, and one year after the last course of RLT. Results: Study showed decreasing of all blood parameters in long-term observation, especially in lymphocytes line. Type of radioisotope, other diseases, primary tumor location, BMI, gender or age did not affect results. The only factor that had influence on hemoglobin and erythrocytes was decreased renal filtration. In long-term observation almost 10% decrease of renal filtration was observed. Type of isotope, gender, age, BMI did not affect these results. Moreover, reduction of urine IL-18, KIM-1, and albumin concentration has been observed. Conclusions: Though low-grade complications of radioligand therapy are possible, it stay a safe method of NEN treatment where benefits outweigh the risk. |
| first_indexed | 2024-03-09T09:43:33Z |
| format | Article |
| id | doaj.art-52204ebc1061443987b0cd66db2bb7d3 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-09T09:43:33Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-52204ebc1061443987b0cd66db2bb7d32023-12-02T00:46:25ZengMDPI AGNutrients2072-66432022-12-0115118510.3390/nu15010185Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine NeoplasmsMarek Saracyn0Adam Daniel Durma1Barbara Bober2Maciej Kołodziej3Arkadiusz Lubas4Waldemar Kapusta5Stanisław Niemczyk6Grzegorz Kamiński7Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandDepartment of Endocrinology and Radioisotope Therapy, Military Institute of Medicine—National Research Institute, 04-141 Warsaw, PolandBackground: Neuroendocrine neoplasms are a group of tumors deriving from neural crest. They can be located in every tissue, but most commonly in gastrointestinal tract. Targeted therapy with use of radionuclides is an available and acceptable way of treatment, but its long-term safety is still to be determined, especially with sensitive methods. Methods: Study was performed on a group of 42 patients. They underwent full cycle (4 courses; 8–12 weekly intervals) of radioligand therapy with [<sup>177</sup>Lu]Lu-DOTATATE alone or tandem therapy with [<sup>177</sup>Lu]Lu-DOTATATE+[<sup>90</sup>Y]Y-DOTATATE. Late and long-term marrow and renal complications were assessed. Analysis focused on comparing data before first, fourth, and one year after the last course of RLT. Results: Study showed decreasing of all blood parameters in long-term observation, especially in lymphocytes line. Type of radioisotope, other diseases, primary tumor location, BMI, gender or age did not affect results. The only factor that had influence on hemoglobin and erythrocytes was decreased renal filtration. In long-term observation almost 10% decrease of renal filtration was observed. Type of isotope, gender, age, BMI did not affect these results. Moreover, reduction of urine IL-18, KIM-1, and albumin concentration has been observed. Conclusions: Though low-grade complications of radioligand therapy are possible, it stay a safe method of NEN treatment where benefits outweigh the risk.https://www.mdpi.com/2072-6643/15/1/185RLTPRRTmyelotoxicitynephrotoxicityrenalhematological |
| spellingShingle | Marek Saracyn Adam Daniel Durma Barbara Bober Maciej Kołodziej Arkadiusz Lubas Waldemar Kapusta Stanisław Niemczyk Grzegorz Kamiński Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms Nutrients RLT PRRT myelotoxicity nephrotoxicity renal hematological |
| title | Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms |
| title_full | Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms |
| title_fullStr | Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms |
| title_full_unstemmed | Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms |
| title_short | Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms |
| title_sort | long term complications of radioligand therapy with lutetium 177 and yttrium 90 in patients with neuroendocrine neoplasms |
| topic | RLT PRRT myelotoxicity nephrotoxicity renal hematological |
| url | https://www.mdpi.com/2072-6643/15/1/185 |
| work_keys_str_mv | AT mareksaracyn longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT adamdanieldurma longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT barbarabober longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT maciejkołodziej longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT arkadiuszlubas longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT waldemarkapusta longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT stanisławniemczyk longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms AT grzegorzkaminski longtermcomplicationsofradioligandtherapywithlutetium177andyttrium90inpatientswithneuroendocrineneoplasms |